Adocia Files Patent for AdoXLong Platform to Extend Peptide Therapy Duration to Monthly Injections
Key Insights
Adocia has filed a patent for its AdoXLong platform, a new long-acting peptide technology that could extend treatment duration to at least one month for diabetes and obesity therapies.
The platform uses biocompatible polymers chemically linked to peptides without altering their mechanisms of action, with early semaglutide results showing promise for once-monthly injections.
The technology is designed to work with various peptides including GLP-1 (search), GIP (search), amylin and dual/triple agonists, potentially improving treatment persistence while reducing manufacturing capacity requirements.
French biopharmaceutical company Adocia has announced the filing of a patent for its AdoXLong platform, a novel long-acting peptide technology designed to extend the duration of action of acylated peptides to at least one month. The development represents a significant advancement in diabetes and obesity treatment delivery, potentially transforming patient experience from weekly to monthly injections.
Technology Platform Details
The AdoXLong platform utilizes biocompatible polymers chemically linked to peptides without altering their mechanisms of action. According to Adocia, the resulting pharmaceutical products are low viscosity aqueous solutions suitable for subcutaneous injection using standard devices. The technology is designed to work with a broad range of peptides including GLP-1 (search), GIP (search), amylin and dual/triple agonists.
The patent's initial application focuses on semaglutide, with Adocia reporting "promising in vitro and in vivo preliminary results indicating efficacy compatible with a once-monthly injection." If granted, the patent is expected to offer worldwide protection until 2046.
Clinical and Manufacturing Advantages
Adocia stated that the technology "would significantly improve long-term treatment persistence, while reducing the manufacturing capacity required per patient, thereby increasing the number of patients who can be treated." This approach addresses key challenges in metabolic disease management, where treatment adherence remains a critical factor in therapeutic success.
Olivier Soula, Chief Executive Officer and co-founder of Adocia, explained the strategic development: "We have leveraged the experience and insights gained from the AdoGel platform to adopt a different technical approach with AdoXLong, a promising platform targeting a patient experience as simple and comfortable as a weekly injection, while ensuring seamless integration into existing manufacturing processes."
BioChaperone Platform Progress
Alongside the AdoXLong announcement, Adocia provided updates on its BioChaperone platform, which stabilizes and combines hormones for metabolic treatments. The company has two ongoing feasibility studies with BioChaperone in collaboration with two large global pharmaceutical companies whose names remain undisclosed.
The last preclinical results obtained with BioChaperone CagriSema were presented during the annual PODD event (Partnership Opportunities in Drug Delivery) in Boston, USA, on October 27-28, 2025. Soula expressed confidence in the platform's potential: "Regarding BioChaperone, we remain confident in the value of the platform for obesity treatments, as evidenced by the two ongoing feasibility studies."
Company Portfolio
Adocia maintains a comprehensive portfolio of drug candidates based on four proprietary technology platforms: the BioChaperone for peptide formulations and combinations, AdOral for oral peptide delivery, AdoShell for immunoprotective biomaterial in cell transplantation, and the newly announced AdoXLong for long-acting peptides. The Lyon-based company holds more than 25 patent families and employs approximately 80 people.